Galapagos NV is a Belgo-Dutch pharmaceutical research company which was founded in 1999. The company started as a joint venture between Crucell - a Leiden based biotech company - and Belgian Tibotec. Currently it has drugs under investigation against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis and systemic lupus erythematosus. The stocks are traded at Euronext Amsterdam and Euronext Brussels under ticker GLPG and at the U.S. OTC market under the ticker symbol GLPYY. The CEO is the Dutchman Onno van de Stolpe. The headquarters are located in Mechelen, Belgium. Also Galapagos holds branches in Leiden, Romainville (France) and Zagreb (Croatia).

Property Value
dbo:abstract
  • Galapagos NV is a Belgo-Dutch pharmaceutical research company which was founded in 1999. The company started as a joint venture between Crucell - a Leiden based biotech company - and Belgian Tibotec. Currently it has drugs under investigation against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis and systemic lupus erythematosus. The stocks are traded at Euronext Amsterdam and Euronext Brussels under ticker GLPG and at the U.S. OTC market under the ticker symbol GLPYY. The CEO is the Dutchman Onno van de Stolpe. The headquarters are located in Mechelen, Belgium. Also Galapagos holds branches in Leiden, Romainville (France) and Zagreb (Croatia). (en)
dbo:assets
  • 1.11E8
dbo:equity
  • 1.41E8
dbo:foundingYear
  • 1999-01-01 (xsd:date)
dbo:industry
dbo:internationally
  • 1 (xsd:integer)
dbo:keyPerson
dbo:location
dbo:numberOfEmployees
  • 400 (xsd:integer)
dbo:operatingIncome
  • 1.52E8
dbo:product
dbo:revenue
  • 1.6E8
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 45514676 (xsd:integer)
dbo:wikiPageRevisionID
  • 741953073 (xsd:integer)
dct:subject
http://purl.org/linguistics/gold/hypernym
georss:point
  • 51.055277777777775 4.452222222222222
rdf:type
rdfs:comment
  • Galapagos NV is a Belgo-Dutch pharmaceutical research company which was founded in 1999. The company started as a joint venture between Crucell - a Leiden based biotech company - and Belgian Tibotec. Currently it has drugs under investigation against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis and systemic lupus erythematosus. The stocks are traded at Euronext Amsterdam and Euronext Brussels under ticker GLPG and at the U.S. OTC market under the ticker symbol GLPYY. The CEO is the Dutchman Onno van de Stolpe. The headquarters are located in Mechelen, Belgium. Also Galapagos holds branches in Leiden, Romainville (France) and Zagreb (Croatia). (en)
rdfs:label
  • Galápagos NV (en)
owl:sameAs
geo:geometry
  • POINT(4.4522223472595 51.055278778076)
geo:lat
  • 51.055279 (xsd:float)
geo:long
  • 4.452222 (xsd:float)
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Galapagos NV (en)
is dbo:wikiPageDisambiguates of
is owl:sameAs of
is foaf:primaryTopic of